- Heymann WR. Cutaneous adverse reactions to Bruton tyrosine kinase inhibitors: Banal to brutal. J Am Acad Dermatol. 2023;88(6):1263–1264. doi:10.1016/j.jaad.2023.03.048.
- Nocco S, Andriano TM, Bose A, et al. Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2022;174:103696. doi:10.1016/j.critrevonc.2022.103696.
- Singer S, Tan SY, Dewan AK, et al. Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor-induced dermatologic adverse events. J Am Acad Dermatol. 2023;88(6):1271–1281. doi:10.1016/j.jaad.2019.12.031.
- Madroñero MG, Martin MIB, Fenollera PS, Blanco LV, Parraga FJP, Encinas MP. 5PSQ-069 Basal cell epithelioma induced by ibrutinib: two case reports. Eur J Hosp Pharm. 2018;25(Suppl 1):A196.2–A197. doi:10.1136/ejhpharm-2018-eahpconf.423.
- Bond DA, Huang Y, Fisher JL, et al. Second cancer incidence in CLL patients receiving BTK inhibitors. Leukemia. 2020;34(12):3197–3205. doi:10.1038/s41375-020-0987-6.
- Sun X, Ma Z, Guo Q, Zhao Z, Liu L. Ibrutinib-related skin cancer: a pharmacovigilance study from the Food and Drug Administration Adverse Event Reporting System. Eur J Cancer. 2022;160:277–278. doi:10.1016/j.ejca.2021.10.034.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 37, 2024 - Issue 2
Clinician’s Corner
An eruption of basal cell carcinoma after ibrutinib
Sharon PanDepartment of Dermatology, Baylor Scott and White Medical Center - Temple, Temple, Texas, USA
https://orcid.org/0000-0001-5872-240X
, MShttps://orcid.org/0000-0001-5872-240X & , MD